SGLT2 Inhibitors Market Size, Share & Trends Analysis Report By Drug (Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin, Ipragliflozin, Sotagliflozin, Others), By Indication (Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease, Weight Management, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: December 23, 2025 | Author: Debashree B | Format:

Table Of Content

  1. Executive Summary

  2. Research Scope & Segmentation
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
  3. Market Opportunity Assessment
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
  4. Market Trends
    1. Drivers
    2. Market Warning Factors
    3. Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
  5. Market Assessment
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
  6. SGLT2 Inhibitors Market Size Analysis
    1. Introduction
    2. SGLT2 Inhibitors Market Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
      1. Canagliflozin
      2. Dapagliflozin
      3. Empagliflozin
      4. Ertugliflozin
      5. Ipragliflozin
      6. Sotagliflozin
      7. Others
    3. SGLT2 Inhibitors Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Type 2 Diabetes
      2. Cardiovascular
      3. Chronic Kidney Disease 
      4. Weight Management
      5. Others
    4. SGLT2 Inhibitors Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
  7. North America SGLT2 Inhibitors Market Size Analysis
    1. Introduction
    2. SGLT2 Inhibitors Market Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
      1. Canagliflozin
      2. Dapagliflozin
      3. Empagliflozin
      4. Ertugliflozin
      5. Ipragliflozin
      6. Sotagliflozin
      7. Others
    3. SGLT2 Inhibitors Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Type 2 Diabetes
      2. Cardiovascular
      3. Chronic Kidney Disease 
      4. Weight Management
      5. Others
    4. SGLT2 Inhibitors Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
    5. U.S.
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    6. Canada
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
  8. Europe SGLT2 Inhibitors Market Size Analysis
    1. Introduction
    2. SGLT2 Inhibitors Market Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
      1. Canagliflozin
      2. Dapagliflozin
      3. Empagliflozin
      4. Ertugliflozin
      5. Ipragliflozin
      6. Sotagliflozin
      7. Others
    3. SGLT2 Inhibitors Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Type 2 Diabetes
      2. Cardiovascular
      3. Chronic Kidney Disease 
      4. Weight Management
      5. Others
    4. SGLT2 Inhibitors Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
    5. U.K.
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    6. Germany
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    7. France
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    8. Spain
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    9. Italy
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    10. Russia
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    11. Nordic
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    12. Benelux
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    13. Rest of Europe
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
  9. APAC SGLT2 Inhibitors Market Size Analysis
    1. Introduction
    2. SGLT2 Inhibitors Market Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
      1. Canagliflozin
      2. Dapagliflozin
      3. Empagliflozin
      4. Ertugliflozin
      5. Ipragliflozin
      6. Sotagliflozin
      7. Others
    3. SGLT2 Inhibitors Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Type 2 Diabetes
      2. Cardiovascular
      3. Chronic Kidney Disease 
      4. Weight Management
      5. Others
    4. SGLT2 Inhibitors Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
    5. China
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    6. Korea
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    7. Japan
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    8. India
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    9. Australia
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    10. Taiwan
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    11. South East Asia
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    12. Rest of Asia-Pacific
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
  10. Middle East and Africa SGLT2 Inhibitors Market Size Analysis
    1. Introduction
    2. SGLT2 Inhibitors Market Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
      1. Canagliflozin
      2. Dapagliflozin
      3. Empagliflozin
      4. Ertugliflozin
      5. Ipragliflozin
      6. Sotagliflozin
      7. Others
    3. SGLT2 Inhibitors Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Type 2 Diabetes
      2. Cardiovascular
      3. Chronic Kidney Disease 
      4. Weight Management
      5. Others
    4. SGLT2 Inhibitors Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
    5. UAE
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    6. Turkey
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    7. Saudi Arabia
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    8. South Africa
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    9. Egypt
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    10. Nigeria
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    11. Rest of MEA
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
  11. LATAM SGLT2 Inhibitors Market Size Analysis
    1. Introduction
    2. SGLT2 Inhibitors Market Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
      1. Canagliflozin
      2. Dapagliflozin
      3. Empagliflozin
      4. Ertugliflozin
      5. Ipragliflozin
      6. Sotagliflozin
      7. Others
    3. SGLT2 Inhibitors Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Type 2 Diabetes
      2. Cardiovascular
      3. Chronic Kidney Disease 
      4. Weight Management
      5. Others
    4. SGLT2 Inhibitors Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
    5. Brazil
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    6. Mexico
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    7. Argentina
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    8. Chile
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    9. Colombia
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
    10. Rest of LATAM
      1. Introduction
      2. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      3. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      4. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
  12. Competitive Landscape
    1. SGLT2 Inhibitors Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    3. Tier Structure Analysis
    4. Recent Developments
  13. Market Players Assessment
    1. Arena Pharmaceuticals
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Astellas Pharma
    3. AstraZeneca
    4. Boehringer Ingelheim
    5. Chong Kun Dang
    6. Cipla Ltd.
    7. Dr Reddy's Laboratories
    8. Eli Lilly and Company
    9. Glenmark Pharma
    10. Janssen Pharmaceuticals
    11. Lupin Ltd.
    12. Merck & Co. Inc.
    13. Otsuka Pharmaceutical
    14. Sumitomo Pharma
    15. Sun Pharmaceutical Ltd.
    16. Taisho Pharma
    17. Torrent Pharma
    18. Zydus Lifesciences
    19. Others
  14. Research Methodology
    1. Research Data
      1. Secondary Data
        1. Major Secondary Sources
        2. Key Data from Secondary Sources
      2. Primary Data
        1. Key Data from Primary Sources
        2. Breakdown of Primaries
      3. Secondary And Primary Research
        1. Key Industry Insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
  15. Appendix
    1. Discussion Guide
    2. Customization Options
    3. Related Reports

  16. Disclaimer

We are featured on: